Merrimack Pharmaceuticals Inc. (MACK) reported that its fourth-quarter net loss attributable to the company widened to $24.77 million from $18.12 million in the same quarter last year. On a per share basis, net loss was $0.26, compared to $1.76 in the prior year.
Collaboration revenues for the quarter rose to $14.19 million from $12.58 million in the year ago quarter.
The company expects its existing unrestricted cash and cash equivalents and available-for-sale securities on hand as of December 31, 2012 of $110.0 million, anticipated interest income and research and development and manufacturing funding under its license and collaboration agreement with Sanofi related to MM-121 to be sufficient to fund operations into 2014.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.26 per share on revenues of $11.77 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.